|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
US20040049014A1
(en)
|
1988-12-28 |
2004-03-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
EP0519596B1
(en)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
A method for reducing the immunogenicity of antibody variable domains
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
CA2204183A1
(en)
|
1994-11-01 |
1996-05-09 |
Andrew Lawrence Feldhaus |
Chimeric receptors for the generation of selectively-activatable th-independent cytotoxic t cells
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
DE19608769C1
(de)
|
1996-03-07 |
1997-04-10 |
Univ Eberhard Karls |
Antikörper BV10A4H2
|
|
EP1958962A3
(en)
|
1997-06-12 |
2013-05-01 |
Novartis International Pharmaceutical Ltd. |
Artificial antibody polypeptides
|
|
DE19727814C1
(de)
|
1997-06-30 |
1998-10-01 |
Univ Eberhard Karls |
Anitkörper 4G8B4B12
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
GB9925853D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
GB9925854D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
US7183385B2
(en)
|
2002-02-20 |
2007-02-27 |
Cell Signaling Technology, Inc. |
Phospho-specific antibodies to Flt3 and uses thereof
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US8546541B2
(en)
|
2002-06-20 |
2013-10-01 |
Washington University |
Compositions and methods for modulating lymphocyte activity
|
|
EP1539218A4
(en)
|
2002-06-20 |
2007-08-22 |
Univ California |
COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
|
|
GB0225279D0
(en)
|
2002-10-30 |
2002-12-11 |
Celltech R&D Ltd |
Biological products
|
|
ZA200503075B
(en)
|
2002-11-07 |
2006-09-27 |
Immunogen Inc |
Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
|
|
EP2322547A1
(en)
*
|
2003-06-25 |
2011-05-18 |
Crucell Holland B.V. |
Myeloid cell-specific lectin
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
AU2007317333A1
(en)
|
2006-11-02 |
2008-05-15 |
Seattle Genetics, Inc. |
Methods of treating neoplastic, autoimmune and inflammatory diseases
|
|
SI2856876T1
(en)
|
2007-03-30 |
2018-04-30 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
AR071891A1
(es)
*
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
|
EP2331566B1
(en)
|
2008-08-26 |
2015-10-07 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
DE102009045006A1
(de)
|
2009-09-25 |
2011-04-14 |
Technische Universität Dresden |
Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
|
|
DK2516468T3
(en)
|
2009-12-23 |
2016-05-23 |
Synimmune Gmbh |
ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
|
|
ES2602743T3
(es)
|
2010-09-08 |
2017-02-22 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Receptores de antígenos quiméricos con una región bisagra optimizada
|
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CA2832540C
(en)
|
2011-04-08 |
2020-09-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
|
|
CA2861491C
(en)
|
2012-02-13 |
2020-08-25 |
Seattle Children's Hospital D/B/A Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
US20130280220A1
(en)
|
2012-04-20 |
2013-10-24 |
Nabil Ahmed |
Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
MX370148B
(es)
|
2012-10-02 |
2019-12-03 |
Memorial Sloan Kettering Cancer Center |
Composiciones y su uso para inmunoterapia.
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
HRP20190366T1
(hr)
*
|
2012-10-12 |
2019-04-19 |
Medimmune Limited |
Pirolobenzodiazepini i njihovi konjugati
|
|
IL311390A
(en)
|
2013-03-15 |
2024-05-01 |
Memorial Sloan Kettering Cancer Center |
Preparations and methods for immunotherapy
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
MX373687B
(es)
|
2013-11-21 |
2020-07-07 |
Ucl Business Ltd |
Célula natural (nk)
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
CN106795221B
(zh)
|
2014-04-03 |
2022-06-07 |
塞勒克提斯公司 |
用于癌症免疫治疗的cd33特异性嵌合抗原受体
|
|
DK3143134T3
(da)
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
EP4205749A1
(en)
*
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
CN105384823A
(zh)
|
2014-08-26 |
2016-03-09 |
中国人民解放军总医院 |
嵌合抗原受体及其基因和重组表达载体、工程化cd33靶向性的nkt细胞及其应用
|
|
EP2990416B1
(en)
|
2014-08-29 |
2018-06-20 |
GEMoaB Monoclonals GmbH |
Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
MA41538A
(fr)
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
WO2016075612A1
(en)
|
2014-11-12 |
2016-05-19 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
|
CA2969384A1
(en)
|
2014-12-17 |
2016-06-23 |
Cellectis |
Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
|
|
EP3233900A2
(en)
|
2014-12-19 |
2017-10-25 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptors and methods of use thereof
|
|
JP6797803B2
(ja)
|
2014-12-31 |
2020-12-09 |
セルジーン コーポレイション |
ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
|
|
JP6849600B6
(ja)
|
2015-01-29 |
2021-06-30 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
キメラ抗原受容体、組成物及び方法
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP4406604A3
(en)
|
2015-03-05 |
2024-10-23 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
EP3268038B1
(en)
|
2015-03-09 |
2021-05-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507115D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
WO2016174652A1
(en)
|
2015-04-30 |
2016-11-03 |
Technion Research & Development Foundation Limited |
Chimeric antigen receptors and methods of their use
|
|
WO2016179319A1
(en)
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
|
CN104829733B
(zh)
|
2015-05-25 |
2018-06-05 |
广州百暨基因科技有限公司 |
抗原结合单元稳定的嵌合抗原受体及制备方法与应用
|
|
HK1252675A1
(zh)
|
2015-06-12 |
2019-05-31 |
Alector Llc |
抗cd33抗体及其使用方法
|
|
AU2016276981B2
(en)
|
2015-06-12 |
2022-10-06 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
US11655452B2
(en)
*
|
2015-06-25 |
2023-05-23 |
Icell Gene Therapeutics Inc. |
Chimeric antigen receptors (CARs), compositions and methods of use thereof
|
|
CN104877032B
(zh)
|
2015-06-26 |
2018-12-11 |
中国医学科学院血液病医院（血液学研究所） |
Cd33特异性嵌合抗原受体及其应用
|
|
HK1255161A1
(zh)
|
2015-07-15 |
2019-08-09 |
Juno Therapeutics, Inc. |
用於过继性细胞治疗的工程细胞
|
|
EP3322439A4
(en)
|
2015-07-16 |
2019-03-20 |
Prospect Chartercare RWMC LLC D/B/A Roger Williams Medical Center |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF PERITONEAL CARCINOMA
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
AU2016306209B2
(en)
|
2015-08-07 |
2023-07-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific CAR T-cells for solid tumor targeting
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
EP3569244A1
(en)
|
2015-09-23 |
2019-11-20 |
CytoImmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
US20180291080A1
(en)
|
2015-09-28 |
2018-10-11 |
Trustees Of Dartmouth College |
Chimeric antigen receptor, regulatory cells and methods of use
|
|
GB201518817D0
(en)
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
WO2017143076A1
(en)
|
2016-02-16 |
2017-08-24 |
Dana-Farber Cancer Institute, Inc. |
Chimeric antigen receptors and methods of use thereof
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
IL262061B2
(en)
|
2016-04-01 |
2023-03-01 |
Amgen Inc |
Chimeric flt-3 receptors and methods of using them
|
|
ES2891578T3
(es)
|
2016-04-01 |
2022-01-28 |
Kite Pharma Inc |
Antígeno quimérico y receptores de células T y métodos de uso
|
|
WO2017176760A2
(en)
|
2016-04-04 |
2017-10-12 |
Vladislav Sandler |
Method of eliminating hematopoietic stem cells/hematopoietic progenitors (hsc/hp) in a patient using bi-specific antibodies
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
CN105820255B
(zh)
|
2016-04-12 |
2019-06-28 |
上海优卡迪生物医药科技有限公司 |
抗cd33嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
US12060394B2
(en)
|
2016-04-28 |
2024-08-13 |
The Trustees Of Dartmouth College |
Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof
|
|
WO2017193059A1
(en)
|
2016-05-06 |
2017-11-09 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
CA3025516A1
(en)
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
|
CA3025667A1
(en)
|
2016-06-08 |
2017-12-14 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
CN109562126A
(zh)
*
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
WO2018027197A1
(en)
|
2016-08-04 |
2018-02-08 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
|
ES2981703T3
(es)
|
2016-09-02 |
2024-10-10 |
Lentigen Tech Inc |
Composiciones y métodos para tratar cáncer con DuoCars
|
|
BR112019006006A2
(pt)
|
2016-09-28 |
2019-06-25 |
Gavish-Galilee Bio Applications Ltd. |
molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico.
|
|
EP3523323A4
(en)
|
2016-10-07 |
2020-06-17 |
Board of Regents, The University of Texas System |
T-CELLS WITH EXPRESSION OF MEMBRANE-ANCHORED IL-12 FOR THE TREATMENT OF CANCER
|
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
AU2017382883B2
(en)
|
2016-12-21 |
2024-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
|
US20180100016A1
(en)
|
2016-12-22 |
2018-04-12 |
Xiaotong Song |
Use of car-modified human natural killer cells to treat cancer
|
|
CN106749675B
(zh)
|
2016-12-27 |
2022-05-27 |
深圳市体内生物医药科技有限公司 |
一种重组慢病毒及其应用
|
|
EP3567049A4
(en)
|
2016-12-28 |
2020-08-26 |
Green Cross Lab Cell Corporation |
CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
|
|
EP3568466A4
(en)
|
2017-01-10 |
2020-07-15 |
The General Hospital Corporation |
TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS
|
|
CA3057838A1
(en)
|
2017-03-24 |
2018-09-27 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd33 immunotherapy
|
|
WO2018183941A2
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
|
US12378297B2
(en)
|
2017-04-14 |
2025-08-05 |
The General Hospital Corporation |
Chimeric antigen receptor T cells targeting the tumor microenvironment
|
|
EP3612210A4
(en)
|
2017-04-19 |
2021-01-27 |
Board Of Regents, The University Of Texas System |
MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
|
|
CN110650975B
(zh)
|
2017-05-15 |
2024-04-05 |
美国卫生和人力服务部 |
双顺反子嵌合抗原受体及其用途
|
|
US12116406B2
(en)
|
2017-05-26 |
2024-10-15 |
Fred Hutchinson Cancer Center |
Anti-CD33 antibodies and uses thereof
|
|
SG10202108528QA
(en)
|
2017-06-02 |
2021-09-29 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
|
CN107337736B
(zh)
|
2017-06-06 |
2019-07-26 |
上海优卡迪生物医药科技有限公司 |
Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
|
|
US11434290B2
(en)
|
2017-06-08 |
2022-09-06 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Chimeric antigen receptors with enhanced NFκB signaling
|
|
CA3287539A1
(en)
*
|
2017-06-21 |
2026-03-02 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
CN107353343A
(zh)
|
2017-07-04 |
2017-11-17 |
武汉波睿达生物科技有限公司 |
一种靶向表达cd33表面抗原的细胞的嵌合抗原受体
|
|
KR20200027508A
(ko)
|
2017-07-07 |
2020-03-12 |
에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 |
돌연변이된 cd28 공동자극 도메인을 갖는 키메라 항원 수용체
|
|
MX2020000686A
(es)
|
2017-07-20 |
2020-07-29 |
H Lee Moffitt Cancer Ct & Res |
Composiciones y métodos para el direccionamiento de cánceres que expresan cd33.
|
|
EP3661511A1
(en)
*
|
2017-08-01 |
2020-06-10 |
Julius-Maximilians-Universität Würzburg |
Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
|
|
AU2018329741B2
(en)
|
2017-09-08 |
2025-02-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
|
|
JP2021500859A
(ja)
|
2017-09-22 |
2021-01-14 |
エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド |
Ｎｆｋｂシグナル伝達の増強を伴うキメラ抗原受容体
|
|
US20190091310A1
(en)
|
2017-09-26 |
2019-03-28 |
Stephen E. Wright |
Nonreleased il-12 for therapy of cancer
|
|
WO2019068007A1
(en)
*
|
2017-09-28 |
2019-04-04 |
Immpact-Bio Ltd. |
UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
|
|
CN117721084A
(zh)
*
|
2017-10-12 |
2024-03-19 |
美商生物细胞基因治疗有限公司 |
靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法
|
|
US11771718B2
(en)
|
2017-10-18 |
2023-10-03 |
Precigen, Inc. |
Polypeptide compositions comprising spacers
|
|
US12053490B2
(en)
|
2017-10-26 |
2024-08-06 |
St. Jude Children's Research Hospital, Inc. |
Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells
|
|
WO2019089813A1
(en)
|
2017-11-01 |
2019-05-09 |
Nantkwest, Inc. |
Nk-92 cells to stimulate anti-cancer vaccine
|
|
EP3710471A1
(en)
|
2017-11-16 |
2020-09-23 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
MA51428A
(fr)
|
2017-12-22 |
2020-11-04 |
Bluebird Bio Inc |
Récepteur d'antigène chimérique multivalent
|
|
CN108060136A
(zh)
|
2017-12-26 |
2018-05-22 |
东莞赛尔生物科技有限公司 |
一种用于治疗aml的嵌合抗原受体t细胞、制备方法及应用
|
|
JP7416695B2
(ja)
|
2017-12-29 |
2024-01-17 |
メモリアル スローン－ケタリング キャンサー センター |
増強されたキメラ抗原受容体およびその使用
|
|
CN108047333B
(zh)
|
2018-01-15 |
2021-05-25 |
浙江阿思科力生物科技有限公司 |
以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用
|
|
CN108251442B
(zh)
|
2018-02-07 |
2022-04-19 |
中国医学科学院血液病医院(中国医学科学院血液学研究所) |
Flt3嵌合抗原受体及其应用
|
|
BR112020016944A2
(pt)
|
2018-02-20 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Domínios variáveis de anticorpo que alvejam cd33 e uso dos mesmos
|
|
WO2019164930A1
(en)
*
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
AU2019224051A1
(en)
|
2018-02-26 |
2020-09-03 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
CA3091224A1
(en)
|
2018-03-12 |
2019-09-19 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
EA202092044A1
(ru)
|
2018-03-14 |
2021-03-03 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные рецепторы антигена против cd33 и их применения
|
|
US12077598B2
(en)
|
2018-03-16 |
2024-09-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Chimeric antigen receptors with mutated CD28 phosphorylation sites
|
|
US20210017248A1
(en)
|
2018-03-16 |
2021-01-21 |
The Regents Of The University Of California |
Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells
|
|
EP3781176A4
(en)
|
2018-04-09 |
2022-05-25 |
The Trustees of the University of Pennsylvania |
METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
EP3784256A4
(en)
|
2018-04-27 |
2022-06-29 |
Baylor College of Medicine |
Car t cells with one or more interleukins
|
|
EA202091977A1
(ru)
|
2018-05-28 |
2021-02-09 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
|
|
GB201813178D0
(en)
*
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
US11866494B2
(en)
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
BR112021006100A2
(pt)
*
|
2018-09-28 |
2021-07-20 |
Immpact-Bio Ltd. |
métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
|
|
US20210338729A1
(en)
|
2018-10-12 |
2021-11-04 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
|
|
IL277414B2
(en)
|
2018-11-06 |
2025-04-01 |
Immunitybio Inc |
NK–92 cells with chimeric antigen receptor modification
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
EP3908294A4
(en)
|
2019-01-10 |
2022-12-28 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified cell expansion and uses thereof
|
|
US12410260B2
(en)
|
2019-01-11 |
2025-09-09 |
The University Of North Carolina At Chapel Hill |
Highly modular biepitopic and bispecific CAR-T cells for cancer immunotherapy
|
|
WO2020210719A1
(en)
|
2019-04-10 |
2020-10-15 |
Elevatebio Management, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
WO2020219425A1
(en)
|
2019-04-25 |
2020-10-29 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
|
|
TW202110873A
(zh)
|
2019-04-30 |
2021-03-16 |
美商聖堤生物科技股份有限公司 |
嵌合受體及其使用方法
|
|
AU2020275049A1
(en)
|
2019-05-16 |
2022-01-06 |
Nanjing Legend Biotech Co., Ltd. |
Engineered immune cells comprsing a recognition molecule
|
|
CN114040978B
(zh)
|
2019-05-31 |
2025-10-17 |
希望之城公司 |
用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞
|
|
EP3980453A4
(en)
|
2019-06-07 |
2023-07-05 |
The Trustees of the University of Pennsylvania |
Dual car expressing t cells individually linked to cd28 and 4-1bb
|
|
CN114080452B
(zh)
|
2019-06-27 |
2025-06-03 |
优特力克斯有限公司 |
具有4-1bb共刺激结构域的嵌合抗原受体
|
|
CN112279922B
(zh)
|
2019-07-22 |
2023-07-28 |
南京助天中科科技发展有限公司 |
一种吞噬细胞嵌合抗原受体及其应用
|
|
MX2022001711A
(es)
|
2019-08-09 |
2022-05-10 |
A2 Biotherapeutics Inc |
Receptores en la superficie celular que responden a la perdida de heterocigosidad.
|
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
|
CN112390891B
(zh)
|
2019-08-14 |
2022-06-03 |
苏州方德门达新药开发有限公司 |
嵌合抗原受体及其构建方法和应用
|
|
CN112500492B
(zh)
|
2019-09-13 |
2023-08-04 |
中国科学院分子细胞科学卓越创新中心 |
一种嵌合抗原受体及其用途
|
|
US20210137983A1
(en)
|
2019-11-08 |
2021-05-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Nk cell expansion and uses thereof
|
|
EP4058561A1
(en)
|
2019-11-12 |
2022-09-21 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
|
CN115052887B
(zh)
|
2019-12-11 |
2026-03-31 |
A2生物治疗公司 |
基于lilrb1的嵌合抗原受体
|
|
CN112501125A
(zh)
|
2020-11-30 |
2021-03-16 |
上海斯丹赛生物技术有限公司 |
偶联嵌合抗原受体细胞及其用途
|